

EXHIBIT A

Serial No. _____ File No. 520531-2001 By TIK/SJ
 Title in the Matter of the Application of SCREENING METHODS AND THE USE OF PATENTS
 Applicant(s)/Inventor(s) MAXTINS
 The following due 9-30-03 in the U.S. Patent Office was received in the Patent Office
☐ Affidavit ☐ Declaration ☒ Express Mail Mailing Label # EV345012625ds
☐ Amendment ☒ (separate sheet)
☐ Preliminary Amendment ☒ Check No. 28529 for \$ 1,616.00
☐ Amendment After Final Rejection ☐ Deposit Account Order Form
☐ Request for Extension of Time ☐ Drawing _____ Sheet(s)
☐ Provisional Patent Application ☒ Information Disclosure Statement (WITH REFERENCES)
☐ Application for Patent, including ☒ PTO Form 1449
☐ Pages Specification _____ Claims _____ Abstract _____
☒ Declaration ☒ Oath ☒ Power
☒ Request for Filing Continuation ☒ Application _____ sheets
☐ PCT Request _____ sheets, including
☐ Transmittal Letter ☐ Status Request ☐ Notice of Appeal (triplicate)
☐ Request for Continued Exam (RCE) ☐ Petition ☐ Response
☒ Assignment ☒ Priority Document
☒ ~~Assignment~~ Fee Transmittal ☐ Statement of Use
☐ Claim of Priority ☐ Response to Examiner's Statement
☐ Request for Approval of Drawings ☐ Search Report
☐ Diskette with Sequence Listing ☐ Response to Notice to File Missing Parts
☒ UTILITY PATENT APPLICATION TRANSMITTAL

EXPRESS MAIL 9-30-03
 EV345012625ds



2003 OCT 21 10:00 AM
 DOCKETED

FROMMER LAWRENCE & HAUG, LLP
 745 FIFTH AVENUE
 NEW YORK, NEW YORK 10151

17548 U.S. PTO
 10/674456



09/30/03

© USPTO 2002



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	520531-2001
First Inventor	MARTINS
Title	SCREENING METHODS AND THE USE OF AGENTS IDENTIFIED USING THE SAME
Express Mail Label No.	EV 345012625 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

**Addressed to: Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 40]
(preferred arrangements set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix.
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets _____]
5. Oath or Declaration [Total Pages 3]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76.

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CFR)
 - b. Specification sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☒ Assignment Papers (cover sheet & documents(s))
10. ☐ 37 CFR 3.73(b) Statement of Attorney
(when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Request and Certification under 35 U.S.C. 122(b)(2)(B)(i).
Applicant must attach from PTO/SB/35 or its equivalent.
17. ☐ Other: _____

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional

Prior application information:

☒ Continuation-in-part (CIP)


Examiner: _____

of prior application No.: WO/03/056339

Group/Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number	20999			or <input type="checkbox"/> Correspondence address below	
Name _____					
Address _____					
City _____		State _____		Zip Code _____	
Country _____		Telephone _____		Fax _____	
Name (Print/Type)		Thomas J. Kowalski		32,147	
Angela M. Nigro-Collison		Registration No. (Attorney/Agent)		51,107	
Signature 				Date	
				September 30, 2003	

REFERENCE TO RELATED APPLICATIONS

This Application is a continuation-in-part of International Patent Application PCT/AU02/01754 filed December 30, 2002 and published as International Publication
5 No. WO 03/056339 on July 10, 2003, which claims priority from Australian Provisional Patent Application PR 9764 filed December 27, 2001.

Each of the foregoing applications, and each document cited or referenced in each of the foregoing applications, including during the prosecution of each of the foregoing
10 applications and ("application cited documents"), and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the foregoing applications and articles and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents
15 cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text or in any document hereby incorporated into this text, are hereby incorporated herein by reference. Documents incorporated by reference into this text or any teachings therein may be used in the practice of this invention. Documents incorporated by reference into this text are not admitted to be prior art.

20

It is noted that in this disclosure and particularly in the claims, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists essentially of"
25 have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

"Screening Methods and the Use of Agents Identified Using the same"

Field of the Invention

The present invention relates to agents and methods for treating diseases such as Alzheimer's disease and other diseases with similar causative agents and to methods for identifying agents for use in treating Alzheimer's disease and other diseases with similar causative agents. More particularly, the present invention relates to novel peptides and their use to treat Alzheimer's disease and methods for screening of peptides to identify peptides for use in treating Alzheimer's disease.

10 Background

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised pathologically by the deposition of amyloid plaques and neurofibrillary tangles, and neuronal degeneration, in the brains of affected individuals.

15 The major protein component of the amyloid deposits is a small 4 kDa peptide of 39-43 amino acids termed beta amyloid (β -amyloid or A β). Numerous studies have suggested that A β accumulation and deposition may be critical to AD. The initial deposition of A β and growth of plaques has been suggested to occur via distinct processes. A β may either form higher oligomeric structures or remain in the monomeric form when it is deposited. *In vitro* studies have found that freshly
20 solubilised monomeric A β , at low concentrations, is not toxic to neurons in culture. However, after an aging period of several hours to days A β spontaneously aggregates in solution to form fibrillar entities that are highly neurotoxic. This suggests aggregation is a requirement for A β toxicity.

25 The AD brain has been shown to be under oxidative stress. Oxidative stress is a situation where there is an excess of oxygen free radicals or reactive oxygen species (ROS), which in turn damage surrounding tissue. Important ROS that

damage the surrounding cellular components are the superoxide radical, hydrogen peroxide and the hydroxyl radical.

- Superoxide dismutases (SOD) are metalloenzymes containing a redox-active transition metal (copper, iron or manganese) at the active site. SOD enzymes
- 5 (SODs) dismutate superoxide radicals by electron transfer between superoxide anions and the transition active metal. While low levels of SODs do provide some protection by detoxifying superoxide radicals thereby preventing superoxide mediated cell damage, high levels of these enzymes sensitises cells to oxidative stress by the overproduction of hydrogen peroxide.
- 10 There is data indicative of A β possessing SOD activity and that this activity is copper dependent. These findings have led to the development of copper chelating agents for treating AD. However, whilst copper chelators may inhibit the SOD activity of A β , they are non-specific and the chelation of copper may disrupt essential biochemical functions in the brain and result in undesirable side
- 15 effects.

Other diseases such as type II diabetes, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE) have also been linked with SOD activity.

- 20 The present invention seeks to provide a screening method for identifying agents that more specifically inhibit the SOD activity and/or metal ion binding of causative agents such as A β and thus represent more attractive options for treatment of AD and other SOD related diseases. At the very least, the present invention seeks to provide alternative agents to the agents currently used to treat
- 25 these diseases.

Summary of the Invention

The present invention provides a method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

- 5 (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and
10 isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

The present invention also provides a method for isolating candidate peptides for the treatment of AD the method comprising the steps of:

- 15 (i) contacting a plurality of candidate peptides with a first agent with SOD activity and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and
isolating the unbound peptides;

20 wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

Another aspect of the present invention is a method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:

- 4 -

- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of A β and isolating the bound peptides; and
- 5 (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of A β and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

- 10 A further aspect of the present invention is a method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the zinc binding site of A β and isolating the bound peptides; and
- 15 (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the zinc binding site of A β and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for AD
20 treatment.

The present invention also relates to peptides identified using the method of the invention and in particular to a peptide comprising a sequence selected from the group of sequences:

Met-Thr-Met-Pro-Thr-Met;

25 Pro-Leu-Pro-Gln-Met-Leu; and

Thr-Asn-Pro-Asn-Arg-Arg-Asn-Arg-Thr-Pro-Gln-Met-Leu-Lys-Arg;

or a functional variant thereof.

The present invention also relates to methods for destabilizing multimeric forms of A β and methods for limiting or preventing the aggregation of A β as well as methods of treating various diseases or disorders such as type II diabetes, AD, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE).

Detailed Description of the Invention

10 Screening Methods

The present invention provides a method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

- 15 (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides;

- 20 wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

For the purposes of the present invention "structurally related" agents are agents that are related in terms of their amino acid sequence to the extent that the agents belong to the same class of molecules. For example, human and rat A β are
25 structurally related for the purposes of the present invention. Preferably,

structurally related agents have at least 75% amino acid sequence homology, more preferably at least 90% amino acid sequence homology and even more preferably at least 95-99% amino acid sequence homology.

- 5 The causative agent may be prion protein, A β or amylin. Furthermore, the disease or disorder may be selected from the group comprising: Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE). Preferably, the disease or disorder is AD.

- 10 The SOD activity of an agent may be dependent or otherwise related to the agent binding copper. Thus, the present invention also provides a method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose SOD activity is dependent on binding copper, the method comprising the steps of:

- 15 (i) contacting a plurality of candidate peptides with a first agent with SOD activity that is adapted to specifically bind copper and isolating the bound peptides; and

- (ii) contacting the peptides isolated from step (i) with a second agent that is structurally related to the first agent but is not adapted to bind copper and isolating the unbound peptides;

- 20 wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

- The peptides isolated by screening based on disruption of SOD activity by interfering with copper binding may bind directly to the copper binding site of the first agent and thus directly block or otherwise interfere with copper binding.
- 25 Alternatively, they may bind at a site other than the copper binding site and indirectly block copper binding by causing some conformational change that removes or otherwise affects the copper binding site to the extent that its ability to bind copper is at least diminished and preferably totally removed. It is also

envisaged that peptides isolated using the screening method may disrupt SOD activity without necessarily preventing copper binding.

The present invention provides a method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose toxicity is

5 dependent on binding copper, the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of the causative agent and isolating the bound peptides; and
 - (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of the causative agent and isolating the unbound peptides;
- 10

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

- 15 The first agent may be immobilised or in solution. The first agent may further comprise an isolation means that assists in isolating the peptides bound to the first agent. The isolation means may be any means that is adapted to selectively bind to another agent and includes peptides and antibodies or fragments thereof. Other isolation means are readily apparent to skilled persons and are also
- 20 encompassed by the present invention.

When the first agent is immobilised it may be immobilised by binding it to a surface via a biotin-streptavidin complex or some other alternative protein-protein complex.

- The second agent may be immobilised or in solution. The second agent may
- 25 further comprise an isolation means that assists in isolating the peptides bound to the second agent. The isolation means may be any means that is adapted to selectively bind to another agent and includes peptides, non-peptide molecules

such as peptide mimetics and antibodies or fragments thereof. Other isolation means are readily apparent to skilled persons and are also encompassed by the present invention.

When the second agent is immobilised it may be immobilised by binding it to a surface via a biotin-streptavidin complex or some other alternative protein-protein complex.

Preferably, the method steps (i) and (ii) are repeated to increase the selectivity of the method. When step (i) and (ii) are repeated, the amount of the first agent may be reduced in each repetition. In particular, the amount of the first agent may be reduced about 10 fold in each repetition. Steps (i) and (ii) may be repeated as many times as deemed necessary by a skilled person and preferably is repeated at least 2-3 times.

When steps (i) and (ii) are repeated, the peptides isolated in the first round may be amplified to provide a larger quantity for subsequent rounds. The amplification of the peptides may be achieved by any means apparent to those skilled in the art. Preferably, the peptides are amplified by growing them in a prokaryotic system such as bacteria.

Hereunder specific mention is made to AD. However, it will be appreciated that the screening methods for AD herein may also be applied to identify candidate peptides for treating other disorders that involve a causative agent whose toxicity is dependent on SOD activity and/or binding copper or other metal ions. A skilled person is able to make the necessary modifications to the methods herein to render them applicable to screening for peptides for treating other disorders.

Thus, the present invention also provides a method for isolating candidate peptides for the treatment of AD the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent with SOD activity and isolating the bound peptides; and

- (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

Preferably, the first agent is A β or a portion thereof containing a copper binding site and/or the portion of A β required for SOD activity. Even more preferably, the first agent is human A β such as human A β ₁₋₄₂ or human A β ₁₋₄₀. Alternatively, the first agent may be another mammalian A β that has SOD activity and/or includes a copper binding site such as rabbit, guinea pig, dog, monkey, cow, sheep or polar bear A β .

Preferably, the second agent is A β or a portion thereof that lacks SOD activity and/or a copper binding site. Even more preferably, the second agent is rat A β such as rat A β ₁₋₄₂ or rat A β ₁₋₄₀. Alternatively, the second agent may be another mammalian A β that lacks SOD activity and/or a copper binding site such as mouse A β .

The present invention also provides a method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of A β and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of A β and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

The screening method of the present invention may also be used to identify peptides that are able to affect the zinc binding activity of a causative agent and thus control its aggregation. Thus, the present invention also provides a method for isolating candidate peptides for the treatment of AD, the method comprising

5 the steps of:

- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the zinc binding site of $A\beta$ and isolating the bound peptides; and
 - (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the zinc binding site of $A\beta$ and isolating the unbound peptides;
- 10

wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

The agents used in the method of the present invention may be naturally occurring molecules. However, it will be appreciated that the agents could be non-naturally occurring molecules that have been produced to mimic one or more characteristics of the naturally occurring molecules that are important for the screen. For example, the agent may be a construct comprising or mimicking the portion of the naturally occurring molecule that is required for SOD activity and/or copper binding. These agents can be constructed based on an analysis of the structure of the naturally occurring molecule that defines the parts of the molecule that are involved in copper binding and/or SOD activity. Once these parts are identified peptide mimetics with one or more characteristics of the natural molecule can be designed and used in the screen instead of the naturally occurring molecule.

15

20

25

The method of the present invention may involve the use of phage display to select the peptides of interest. Alternatively, the method of the present invention may involve the use of other techniques that enable the convenient screening of candidate peptides such as the yeast two hybrid system.

The above screening methods relate to the identification of peptides with therapeutic uses. However, it will be appreciated that the methods may also be used to screen for non-peptidic compounds that also have therapeutic uses. These non-peptidic compounds include peptide mimetics with one or more characteristics of the peptides identified using the screening methods described herein and thus may be adapted to block or otherwise reduce the SOD and/or copper binding activity of a causative agent.

Thus, the present invention also provides a method for isolating candidate non-peptidic compounds for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

- (i) contacting a plurality of candidate non-peptidic compounds with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound compounds; and
- (ii) contacting the compounds isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound compounds;

wherein the compounds isolated from step (ii) are candidates for treatment of the disease.

The screening method for non-peptidic compounds may be used to isolate candidates for the treatment of AD, the method comprising the steps of:

- (i) contacting a plurality of candidate non-peptidic compounds with a first agent that is adapted to bind compounds that specifically bind to the copper binding site of A β and isolating the bound compounds; and
- (ii) contacting the compounds isolated from step (i) with a second agent that is adapted to bind compounds isolated from step (i) that do not specifically bind to the copper binding site of A β and isolating the unbound compounds;

wherein the compounds isolated from step (ii) are candidates for AD treatment.

Preferably, the candidate non-peptidic compounds are provided in a database or library that can be conveniently screened. However, the candidate non-peptidic compounds may also be derived from other sources.

5 Peptides

The present invention also provides peptides identified using the screening method of the invention and includes peptides that are adapted to bind to a causative agent such as A β and inhibit its SOD activity and/or its copper and/or zinc binding ability.

- 10 The peptides of the invention adapted to bind to A β include a peptide comprising a sequence selected from the group of sequences:

(i) Met-Thr-Met-Pro-Thr-Met;

(ii) Pro-Leu-Pro-Gln-Met-Leu; and

(iii) Thr-Asn-Pro-Asn-Arg-Arg-Asn-Arg-Thr-Pro-Gln-Met-Leu-Lys-Arg;

- 15 or a functional variant thereof.

Preferably, the peptides of the present invention totally remove SOD activity and/or prevent the causative agent binding copper although, it will be appreciated that peptides that decrease the SOD activity and/or copper binding activity are also useful. The peptides of the present invention may bind to the causative agent such that the copper binding site is no longer able to bind copper or is able to bind it to a lesser extent. In this regard, the peptide may bind at or near the copper binding site and physically prevent the binding of copper. When the peptide binds at or near the copper binding site of A β it preferably binds at or near amino acids 5-14 of A β , more preferably amino acids 8-14 of A β

20

and even more preferably at or near amino acid 13 of A β , which is a histidine residue.

Alternatively, the peptide may bind to the causative agent at a site removed from the copper binding site and disrupt the conformation (or 3-D structure) of the copper binding site to reduce or totally remove its ability to bind copper and/or its SOD activity. When the peptide disrupts the conformation of the copper binding site of A β it preferably binds and disrupts the conformation of amino acids 5-14 of A β , more preferably amino acids 8-14 and even more preferably amino acid 13 of A β .

- 10 In another form of the invention, the peptides are adapted to bind A β in a fashion that does not prevent or reduce copper binding but still has therapeutic effect through at least reducing the SOD activity of the causative agent.

Functional variants also include peptides with modified or different amino acids sequences that still retain their ability to bind to the causative agent and inhibit its SOD activity and/or copper binding ability. These functional variants include peptides with deletions, insertions, inversions, repeats and/or type substitutions. Preferably, functional variants are at least 80% identical to the recited sequence, more preferably at least 90% identical and even more preferably at least 95% identical.

- 20 Functional variants also include peptides (i) in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue such as synthetic, non-naturally occurring analogues and/or natural amino acid residues; or (ii) in which one or more of the amino acid residues includes a substituent group; or (iii) fused with another compound such as a compound to increase the peptide's half life (e.g. water-soluble polymers such as polyethylene glycol); or (iv) fused with additional amino acids such as an IgG Fc fusion region peptide, a leader or secretory sequence, or a sequence that is used to aid the purification or isolation of the peptide e.g. glutathione-S-transferase (GST), hexahistidine, GAL4 (DNA binding and/or transcriptional activation
- 25

- domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion peptide partner and the peptide sequence of interest to allow removal of the fusion sequence. Preferably the fusion sequence does not hinder the binding of the peptide to the causative agent to inhibit its
- 5 SOD activity and/or copper binding ability.

Particular conserved substitutions involve the substitution of a charged amino acid with an alternative charged amino acid or a negatively charged or neutral amino acid. Preferably, the changes are minor and do not have a negative impact on the ability of the peptide to bind to the causative agent and inhibit its

10 copper binding ability and/or its SOD activity. Other conservative substitutions for the purposes of the present invention are exemplified in the table hereunder. However, it will be appreciated that skilled persons may also determine further conservative substitutions not specifically listed.

Aromatic	Phenylalanine Tryptophan Tyrosine Histidine
Hydrophobic	Leucine Isoleucine Valine
Small	Alanine Serine Threonine Methionine Glycine
Acidic	Aspartic acid Glutamic acid
Basic	Arginine

- 15 -

	Lysine Histidine
Polar	Glutamine Asparagine

Amino acids that are essential for the binding of the peptide to the causative agent to inhibit its ability to bind copper and/or remove or decrease its SOD activity may be determined by one skilled in the art using techniques known in the art, such as alanine scanning. Structural analysis such as crystallisation, nuclear magnetic resonance or photoaffinity labelling may also be used when developing functional variants. Alternatively, synthetic peptides corresponding to candidate functional variants may be produced and their ability to bind to the causative agent and inhibit its ability to bind copper and/or remove SOD activity assessed *in vitro*.

It will be appreciated that the amino acids in the peptides of the present invention that are required for binding to the causative agent and/or to remove its SOD activity may be incorporated into larger peptides and still maintain their binding characteristics. Thus, the peptides may be of various sizes provided they maintain their ability to bind the causative agent and/or remove SOD activity. Preferably, the amino acids required for binding are a contiguous sequence of between about 5 and 20 amino acids and more preferably between about 6 and 15 amino acids. As indicated above this contiguous sequence may be incorporated into a larger peptide.

20 Nucleotides

The present invention also provides polynucleotides encoding the peptides of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same peptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may,

using routine techniques, make nucleotide substitutions that do not affect the peptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.

- 5 Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides that include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of
- 10 the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of the invention.
- 15 Where the polynucleotide of the invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention.

20. Therapeutic peptides

- Peptides identified using the screening method of the present invention may be administered therapeutically to patients. It is preferred to use peptides that do not consist solely of naturally-occurring amino acids but which have been modified, for example to reduce immunogenicity, to increase circulatory half-life
- 25 in the body of the patient, to enhance bioavailability and/or to enhance efficacy and/or specificity.

A number of approaches have been used to modify peptides for therapeutic application. One approach is to link the peptides or proteins to a variety of polymers, such as polyethylene glycol (PEG) and polypropylene glycol (PPG).

Replacement of naturally occurring amino acids with a variety of uncoded or modified amino acids such as D-amino acids and N-methyl amino acids may also be used to modify peptides. Another approach is to use bifunctional crosslinkers, such as N-succinimidyl 3-(2 pyridyldithio) propionate, succinimidyl 6-[3-(2

5 pyridyldithio) propionamido] hexanoate, and sulfosuccinimidyl 6-[3-(2 pyridyldithio) propionamido]hexanoate.

It may be desirable to use derivatives of the peptides of the invention that are conformationally constrained. Conformational constraint refers to the stability and preferred conformation of the three-dimensional shape assumed by a

10 peptide. Conformational constraints include local constraints, involving restricting the conformational mobility of a single residue in a peptide; regional constraints, involving restricting the conformational mobility of a group of residues, which residues may form some secondary structural unit; and global constraints, involving the entire peptide structure.

- 15 The active conformation of the peptide may be stabilized by a covalent modification, such as cyclization or by incorporation of gamma-lactam or other types of bridges. For example, side chains can be cyclized to the backbone so as create a L-gamma-lactam moiety on each side of the interaction site. Cyclization also can be achieved, for example, by formation of cystine bridges,
- 20 coupling of amino and carboxy terminal groups of respective terminal amino acids, or coupling of the amino group of a Lys residue or a related homolog with a carboxy group of Asp, Glu or a related homolog. Coupling of the alpha-amino group of a polypeptide with the epsilon-amino group of a lysine residue, using iodoacetic anhydride, can be also undertaken.
- 25 Another approach is to include a metal-ion complexing backbone in the peptide structure. Typically, the preferred metal-peptide backbone is based on the requisite number of particular coordinating groups required by the coordination sphere of a given complexing metal ion. In general, most of the metal ions that may prove useful have a coordination number of four to six. The nature of the
- 30 coordinating groups in the peptide chain includes nitrogen atoms with amine, amide, imidazole, or guanidino functionalities; sulfur atoms of thiols or disulfides;

and oxygen atoms of hydroxy, phenolic, carbonyl, or carboxyl functionalities. In addition, the peptide chain or individual amino acids can be chemically altered to include a coordinating group, such as for example oxime, hydrazino, sulfhydryl, phosphate, cyano, pyridino, piperidino, or morpholino. The peptide construct can be either linear or cyclic, however a linear construct is typically preferred. One example of a small linear peptide is Gly-Gly-Gly-Gly that has four nitrogens (an N₄ complexation system) in the backbone that can complex to a metal ion with a coordination number of four.

- A further technique for improving the properties of therapeutic peptides is to use non-peptide peptidomimetics. A wide variety of useful techniques may be used to elucidating the precise structure of a peptide. These techniques include amino acid sequencing, x-ray crystallography, mass spectroscopy, nuclear magnetic resonance spectroscopy, computer-assisted molecular modelling, peptide mapping, and combinations thereof. Structural analysis of a peptide generally provides a large body of data that comprise the amino acid sequence of the peptide as well as the three-dimensional positioning of its atomic components. From this information, non-peptide peptidomimetics may be designed that have the required chemical functionalities for therapeutic activity but are more stable, for example less susceptible to biological degradation.
- Thus, the present invention also provides for the use of a peptide identified using the screening method described herein for designing a mimetic thereof such as a non-peptide peptidomimetic.

Other methods

- The peptides of the present invention are adapted to bind to the causative agents of disease and remove their SOD activity and/or copper binding ability. Thus, the present invention also provides a method for reducing or removing SOD activity or inhibiting the copper binding ability of a causative agent, the method comprising contacting the causative agent with a peptide identified using the screen of the present invention such that the peptide binds to the causative agent in a fashion that at least reduces its SOD and/or copper binding activity.

Copper is involved in stabilizing multimeric forms of A β . Thus, the present invention also provides a method for destabilizing multimeric forms of A β , the method comprising contacting the multimeric A β with a peptide of the present invention such that the peptide binds to the multimeric A β in a fashion that
5 destabilizes the multimeric A β .

The present invention also provides a method for limiting or preventing the aggregation of A β , the method comprising contacting the A β with a peptide of the present invention such that the peptide binds to the A β and prevents or limits its aggregation.

- 10 The causative agents include prion protein, A β and amylin. Thus, the present invention also comprises treating a disease or disorder selected from the group comprising type II diabetes, AD, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy
15 (BSE) comprising the step of administering an effective amount of a peptide identified using the screening method of the present invention.

Administration

- Peptides of the invention may be combined with various components to produce compositions of the invention. Preferably the compositions are combined with a
20 pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition of the invention may be administered by direct injection. The composition may be formulated for parenteral, intramuscular, intravenous,
25 subcutaneous, intraocular, oral or transdermal administration.

The routes of administration described herein are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient.

The present invention will now be described with reference to the examples that describe one preferred embodiment of the invention. The description of the examples is in no way limiting on the scope of the present invention described elsewhere herein.

5 Examples

Example 1 – Phage Display

The two phage libraries (fUSE 5/6-mer and fUSE 5/15-mer peptide inserts, can be obtained from Professor George P Smith from the University of Missouri, Columbia, MO, USA other suitable phage libraries can be purchased from commercial sources such as New England Biolabs Inc. Bio/Can Scientific Inc, DGI BioTechnologies LLC. NoBiTec, Syncomm Corp, Invitrogen and Stratagene) were each selected with both human A β 40 and human A β 42 separately. The eluted selected phage then were dialysed before being subtracted with rat A β 42 to give unbound fractions of phage. This sub-population therefore contains those peptides, which recognise human A β and have had subtracted, those which also recognise rat A β .

Four rounds of this selection/subtraction protocol are carried out, reducing the quantity of the HA β by "10-fold" each time to encourage selection of the phage clones with the greatest affinity for the target molecule. After four rounds of selection/subtraction DNA is extracted and sequenced to determine level of consensus of sequences. A further three rounds of selection/subtraction are carried out to ensure sufficient duplication of sequences.

Methodology

25 First Round panning pre-reacts the streptavidin with ligate (A β) before adding the phage.

ie. PLATE + LIGATE \rightarrow PLATE-LIGATE + PHAGE

1.	Buffer preparation.
2.	Biotinylation of ligate (A β) [human A β 40 peptide (HA β 40) and human

	A β 42 peptide (HA β 42).
3.	Coat a 6 well sterile plate with Streptavidin (SA) overnight (O/N) at room temperature (RT) with gentle rocking.
4.	Block SA coated plate with buffer A for 1 hr at 37°C with gentle rocking.
5.	Add biotinylated HA β 40 and HA β 42 to SA coated plates and incubate at 37°C for 2 hrs with gentle rocking.
6.	Add 4 μ l of biotin to block remaining binding sites and incubate for a further 1 hr at 37°C.
7.	Wash plate with buffer B, then add 0.4 ml of buffer B to 10 μ l of the 6 mer and 15 mer phage libraries. Add this to the respective well of the SA/biotin plate and incubate at 37°C for 4 hrs.
8.	Discard unbound phage, wash 10 times with buffer B and elute with 0.4 ml of buffer C. Collect eluate into eppendorf tube and add 75 μ l of buffer D.
9.	Dialyse eluates in buffer E with gentle agitation O/N at 4°C.
10.	Biotinylate rat A β 42 peptide (RA β 42) and incubate biotinylated product with 100 μ l of dialysed eluate O/N at 37°C with constant shaking
11.	Coat a 6 well sterile plate with Streptavidin (SA) overnight (O/N) at room temperature (RT) with gentle rocking.
12.	Repeat step 4.
13.	Wash SA plate with buffer B, then add 0.4 ml of buffer B to eluate + biotinylated RA β 42 bound libraries. Add this to the respective well of the SA plate and incubate for 0.5 hr at 37°C then collect the unbound phage and store at 4°C.
14.	Wash bottles, prepare buffers/broths and agars, autoclave and pour plates for growing K91Kan E.coli (without phage).
Amplification for further rounds	
15.	Plate out E.coli for single colonies on TY+Kan agar plates for O/N growth at 37°C.
16.	Pick a single colony and inoculate 1ml of TY broth + Kan. Culture for 5 hrs at 37°C
17.	Mix 100 μ l of unbound phage with 100 μ l of cultured E.coli. and incubate at RT for 20 min, then transfer to tube containing 30 ml of TY +0.2 μ g/ml Tet. Shake for 45 min at 37°C. Then add 30 μ l of 20 mg/ml Tet and shake for 37°C O/N.
18.	Centrifuge tubes for 45 min at 2,500 rpm at RT. Transfer supernatant to a new set of labelled tubes. Add 4.5 ml of buffer F to get rid of the bacteria, mix and incubate at 4°C O/N.
19.	Centrifuge tubes for 45 min at 2,500 rpm at RT. Discard supernatant (pour off) and leave tubes inverted on paper towels for up to 1 hr. Add TBS buffer to each tube, mix phage thoroughly and transfer to labelled eppendorf tube. Centrifuge tube at 10,000 rpm for 3 min. Transfer the supernatant to a freshly labelled eppendorf tube. Add 0.15 ml of buffer F and leave at 4°C O/N.
20.	Centrifuge tube at 10,000 rpm for 10 min. Discard supernatant. Resuspend pellet in 0.2 ml of buffer G and store at 4°C.

The second and subsequent rounds of panning are then carried out. For these rounds the phage is pre-reacted with ligate (A β) before adding it to the streptavidin coated plate.

ie. PHAGE + LIGATE \rightarrow PHAGE-LIGATE + PLATE For round Two

5

Round two and subsequent panning rounds:

1.	Buffer preparation.
2.	Biotinylation of ligate (A β) [human A β 40 peptide (HA β 40) and human A β 42 peptide (HA β 42)].
3.	Incubate biotinylated HA β 40 and HA β 42 peptides with amplified phage (there are four samples ie. 40/6mer, 40/15mer, 42/6mer and 42/15mer) O/N at 37°C.
4.	Coat a 6 well sterile plate with Streptavidin (SA) overnight (O/N) at room temperature (RT) with gentle rocking.
5.	Block SA coated plate with buffer A for 1 hr at 37°C with gentle rocking.
6.	Wash plate with buffer B, then add 0.4 ml of buffer B to the four amplified phage samples. Add samples to the respective well of the SA plate and incubate at 37°C for 0.5 hr.
7.	Discard unbound phage, wash 10 times with buffer B and elute with 0.4 ml of buffer C. Collect eluate into eppendorf tube and add 75 μ l of buffer D.
8.	Dialyse eluates in buffer E with gentle agitation O/N at 4°C.
9.	Biotinylate rat A β 42 peptide (RA β 42) and incubate biotinylated product with 100 μ l of dialysed eluate O/N at 37°C with constant shaking.
10.	Coat a 6 well sterile plate with Streptavidin (SA) overnight (O/N) at room temperature (RT) with gentle rocking.
11.	Repeat step 4.
12.	Wash SA plate with buffer B, then add 0.4 ml of buffer B to eluate + biotinylated RA β 42 bound libraries. Add this to the respective well of the SA plate and incubate for 0.5 hr at 37°C then collect the unbound phage and store at 4°C.
13.	Wash bottles, prepare buffers/broths and agars, autoclave and pour plates for growing K91Kan E.coli (with and without phage).
For Amplification after Round Two and Round Three: See Round One Amplification for further rounds.	
For Amplification of phage for Sequencing (from Round FOUR onwards).	
14.	Prepare plates and plate out E.coli for single colonies on TY+Kan agar plate for O/N growth at 37°C.
15.	Pick a single colony and inoculate 1ml of TY broth + Kan. Culture for 5 hrs at 37°C.
16.	Prepare serial dilutions (10^{-1} , 10^{-2} , 10^{-3} , 10^{-4} , 10^{-5}) of unbound phage.
17.	Mix 20 μ l of neat and diluted phage with 20 μ l of cultured E.coli. and incubate at 37°C for 10 min, then at RT for 15 min. Add 1.0 ml of fresh TY broth to each sample and shake for 30 min at 37°C. Plate out 0.2 ml of each sample onto a separate TY+Kan+Tet agar plate for O/N growth at 37°C.

18.	Select plate with an optimum number of about 20 colonies. Label colonies (A-T). For each A β form for either the 6 mer or 15 mer library, therefore n=4, will have 20 colonies, therefore 20x4=total of 80 colonies. Transfer each colony into its respective labelled tube containing 30 ml of Terrific broth+Kan+Tet (prepare fresh on the day of use). Incubate with shaking O/N at 37°C.
19.	Centrifuge tubes for 45 min at 2,500 rpm at RT. Transfer supernatant to a new set of labelled tubes. Add 4.5 ml of buffer F to get rid of the bacteria, mix and incubate at 4°C O/N.
20.	Centrifuge tubes for 45 min at 2,500 rpm at RT. Discard supernatant (pour off) and leave tubes inverted on paper towels for up to 1 hr. Add TBS buffer to each tube, mix phage thoroughly and transfer to labelled eppendorf tube. Centrifuge tube at 10,000 rpm for 3 min. Transfer the supernatant to a freshly labelled eppendorf tube. Add 0.15 ml of buffer F and leave at 4°C O/N.
21.	Centrifuge tube at 10,000 rpm for 10 min. Discard supernatant. Resuspend pellet in 0.2 ml of buffer G. Extract DNA from phage using M13 kit for first 20 samples.
22.	Finish off DNA extraction from remaining 60 samples.
23.	Measure Absorbance of samples. Determine concentrations and prepare aliquots for sequencing.
24.	Sequencing of DNA. This requires PCR, purify product by ethanol precipitation and run on ABI 310 sequencer. NOTE: THIS IS ONLY FOR ROUNDS 4 TO 7.
25.	Data analysis of all sequences obtained.

- Three candidate peptides were identified when HA β ₁₋₄₂ was used to isolate a sub-population from a whole phage library and then RA β ₁₋₄₂, in excess, was used to 'mop-up' the phage clones that recognise common sites between the two A β molecules. This left behind in the unbound fraction of the applied phage, only those phage clones that specifically recognise those characteristics of HA β ₁₋₄₂ (in the copper binding site) that are unique to this human peptide and which confer on the molecule its SOD activity.

Sequences of three candidate A β binding peptides isolated using the above protocol are:

- Peptide 1: H - Met-Thr-Met-Pro-Thr-Met- OH (Three letter code)
(6-mer) H- M T M P T M - OH (Single letter code)
- Peptide 2: H - Pro-Leu-Pro-Gln-Met-Leu - OH (Three letter code)
(6-mer) H - P L P Q M L - OH (Single letter code)

- 24 -

- Peptide 3: H - Thr-Asn-Pro-Asn-Arg-Arg-Asn-Arg-Thr-Pro-Gln-Met-Leu-
Lys-Arg- OH (Three letter code)
(15-mer) H- T N P N R R N R T P Q M L K R- OH
(Single letter code)

5

Throughout the specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the
10 exclusion of any other integer or group of integers.

The invention will now be further described by the following paragraphs:

1. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

(i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and

(ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

2. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose SOD activity is dependent on binding copper, the method comprising the steps of:

(i) contacting a plurality of candidate peptides with a first agent with SOD activity that is adapted to specifically bind copper and isolating the bound peptides; and

(ii) contacting the peptides isolated from step (i) with a second agent that is structurally related to the first agent but is not adapted to bind copper and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

3. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose toxicity is dependent on binding copper, the method comprising the steps of:

(i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of the causative agent and isolating the bound peptides; and

- (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of the causative agent and isolating the unbound peptides;
- 5 wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

4. A method according to any one of paragraphs 1-3 wherein the first and/or second agent is immobilised.
- 10 5. A method according to any one of paragraphs 1-3 wherein the first and/or second agent is in solution.
6. A method according to any one of paragraphs 1 to 5 wherein the first and/or second agent further comprises an isolation means that assists in isolating the peptides bound thereto.
- 15 7. A method according to any one of paragraphs 1 to 6 wherein the method steps (i) and (ii) are repeated to increase the selectivity of the method.
- 20 8. A method according to paragraph 7 wherein the amount of the first agent is reduced in each repetition.
9. A method according to paragraph 8 wherein the amount of the first agent is reduced about 10 fold in each repetition.
- 25 10. A method according to any one of paragraphs 7-9 wherein steps (i) and (ii) are repeated at least 2-3 times.
- 30 11. A method according to any one of paragraphs 7-10 wherein the peptides isolated in the first round are amplified to provide a larger quantity for subsequent rounds.

12. A method for isolating candidate peptides for the treatment of AD the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent with SOD activity and isolating the bound peptides; and
(ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

13. A method according to paragraph 12 wherein the first agent is A β containing a copper binding site and/or SOD activity or a portion thereof with SOD activity and/or a copper binding site.

14. A method according to paragraph 12 or 13 wherein the first agent is human A β .

15. A method according to paragraph 14 wherein the human A β is human A β ₁₋₄₂ or human A β ₁₋₄₀.

16. A method according to paragraph 12 or 13 wherein the first agent is a non-human mammalian A β .

17. A method according to paragraph 16 wherein the non-human mammalian A β is rabbit guinea pig, dog, monkey, cow, sheep or polar bear A β .

18. A method according to any one of paragraphs 12-17 wherein the second agent is A β that lacks SOD activity and/or a copper binding site or a portion thereof that lacks SOD activity and/or a copper binding site.

19. A method according to paragraph 18 wherein the second agent is rat A β .

20. A method according to paragraph 19 wherein the rat A β is rat A β ₁₋₄₂ or rat A β ₁₋₄₀.

5 21. A method according to paragraph 18 wherein the second agent is a non-rat mammalian A β .

22. A method according to paragraph 21 wherein the non-rat mammalian A β is mouse A β .

10

23. A method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:

(i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of A β and isolating the bound peptides; and

15

(ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of A β and isolating the unbound peptides; wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

20

24. A method according to any one of paragraphs 1 to 23 wherein the agents are naturally occurring molecules.

25. A method according to any one of paragraphs 1 to 23 wherein the agents are non-naturally occurring molecules that have been produced to mimic one or more characteristics of the naturally occurring molecules that are important for the screen.

25

26. A peptide identified using the method according to any one of paragraphs 1 to 25.

30

27. A peptide comprising a sequence selected from the group of sequences:
(i) Met-Thr-Met-Pro-Thr-Met;

(ii) Pro-Leu-Pro-Gln-Met-Leu; and

(iii) Thr-Asn-Pro-Asn-Arg-Arg-Asn-Arg-Thr-Pro-Gln-Met-Leu-Lys-

Arg;

or a functional variant thereof.

5

28. A peptide according to paragraph 26 or 27 that binds at or near a copper binding site of A β and physically prevents the binding of copper.

29. A peptide according to any one of paragraphs 26 to 28 wherein the
10 peptide binds at or near amino acids 5-14 of human A β .

30. A peptide according to any one of paragraphs 26 to 28 wherein the peptide binds at or near amino acids 8-14 of human A β .

31. A peptide according to any one of paragraphs 26 to 28 wherein the
15 peptide binds at or near amino acid 13 of human A β .

32. A peptide according to paragraph 26 or 27 that binds to A β and disrupts the conformation (or 3-D structure) of the copper binding site to reduce or totally
20 remove its ability to bind copper and/or its SOD activity.

33. A peptide according to paragraph 32 that binds and disrupts the conformation of amino acids 5-14 of human A β .

34. A peptide according to paragraph 32 that binds and disrupts the
25 conformation of amino acids 8-14 of human A β .

35. A peptide according to paragraph 32 that binds and disrupts the conformation of amino acid 13 of human A β .

30

36. A peptide according to paragraph 26 or 27 that binds to A β and reduces or totally removes its SOD activity whilst still allowing the A β to bind copper.

37. A functional variant of the peptides of any one of paragraphs 26 to 36.
38. A non-peptide peptidomimetic of a peptide according to any one of
5 paragraphs 26 to 36.
39. A polynucleotide encoding any one of the peptides of paragraphs 26 to
37.
- 10 40. The use of a peptide according to any one of paragraphs 26 to 37 for
designing a mimetic thereof.
41. A method for reducing or removing SOD activity or inhibiting the
copper binding ability of a causative agent, the method comprising contacting the
15 causative agent with a peptide identified using the screen of the present invention such
that the peptide binds to the causative agent in a fashion that at least reduces its SOD
and/or copper binding activity.
42. A method for destabilizing multimeric forms of A β , the method
20 comprising contacting the multimeric A β with a peptide of the present invention such
that the peptide binds to the multimeric A β in a fashion that destabilizes the multimeric
A β .
43. A method for limiting or preventing the aggregation of A β , the method
25 comprising contacting the A β with a peptide of the present invention such that the
peptide binds to the A β and prevents or limits its aggregation.
44. A method of treating a disease or disorder selected from the group
comprising type II diabetes, AD, Scrapie and Transmissible Spongiform
30 Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann
Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE)

comprising the step of administering an effective amount of a peptide identified using the screening method of the present invention.

45. A pharmaceutical composition comprising a peptide of the present
5 invention and a pharmaceutically acceptable carrier or diluent.

46. A method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:

- 10 (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the zinc binding site of A β and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the zinc binding site of A β and isolating the unbound peptides;
- 15 wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

CLAIMS

1. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

- 5 (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and
- (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating
- 10 the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

2. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose SOD activity is dependent on binding copper, the method comprising the steps of:

- 15 (i) contacting a plurality of candidate peptides with a first agent with SOD activity that is adapted to specifically bind copper and isolating the bound peptides; and
- 20 (ii) contacting the peptides isolated from step (i) with a second agent that is structurally related to the first agent but is not adapted to bind copper and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

25 3. A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent whose toxicity is dependent on binding copper, the method comprising the steps of:

- 30 (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of the causative agent and isolating the bound peptides; and

- (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of the causative agent and isolating the unbound peptides;
- 5 wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.
4. A method according to any one of claims 1 to 3 wherein the first and/or second agent is immobilised.
- 10 5. A method according to any one of claims 1 to 3 wherein the first and/or second agent is in solution.
6. A method according to any one of claims 1 to 3 wherein the first and/or second agent further comprises an isolation means that assists in isolating the peptides bound thereto.
- 15 7. A method according to any one of claims 1 to 3 wherein the method steps (i) and (ii) are repeated to increase the selectivity of the method.
- 20 8. A method according to claim 7 wherein the amount of the first agent is reduced in each repetition.
9. A method according to claim 8 wherein the amount of the first agent is reduced about 10 fold in each repetition.
- 25 10. A method according to claim 7 wherein steps (i) and (ii) are repeated at least 2-3 times.
- 30 11. A method according to claim 7 wherein the peptides isolated in the first round are amplified to provide a larger quantity for subsequent rounds.

12. A method for isolating candidate peptides for the treatment of AD the method comprising the steps of:

- (i) contacting a plurality of candidate peptides with a first agent with SOD activity and isolating the bound peptides; and
- 5 (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides;

wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease.

10

13. A method according to claim 12 wherein the first agent is A β containing a copper binding site and/or SOD activity or a portion thereof with SOD activity and/or a copper binding site.

15

14. A method according to claim 12 or 13 wherein the first agent is human A β .

20

15. A method according to claim 14 wherein the human A β is human A β ₁₋₄₂ or human A β ₁₋₄₀.

16. A method according to claim 12 or 13 wherein the first agent is a non-human mammalian A β .

25

17. A method according to claim 16 wherein the non-human mammalian A β is rabbit, guinea pig, dog, monkey, cow, sheep or polar bear A β .

30

18. A method according to claim 12 wherein the second agent is A β that lacks SOD activity and/or a copper binding site or a portion thereof that lacks SOD activity and/or a copper binding site.

19. A method according to claim 18 wherein the second agent is rat A β .

20. A method according to claim 19 wherein the rat A β is rat A β ₁₋₄₂ or rat A β ₁₋₄₀.
21. A method according to claim 18 wherein the second agent is a non-rat
5 mammalian A β .
22. A method according to claim 21 wherein the non-rat mammalian A β is mouse A β .
- 10 23. A method for isolating candidate peptides for the treatment of AD, the method comprising the steps of:
- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the copper binding site of A β and isolating the bound peptides; and
 - 15 (ii) contacting the peptides isolated from step (i) with a second agent that is adapted to bind peptides isolated from step (i) that do not specifically bind to the copper binding site of A β and isolating the unbound peptides;
- wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.
- 20 24. A method according to any one of claims 1 to 3 wherein the first and second agents are naturally occurring molecules.
25. A method according to any one of claims 1 to 3 wherein the first and second agents are non-naturally occurring molecules that have been produced to mimic
25 one or more characteristics of the naturally occurring molecules that are important for the screen.
26. A peptide identified using the method according to any one of claims 1 to 3.
- 30 27. A peptide comprising a sequence selected from the group of sequences:
- (i) Met-Thr-Met-Pro-Thr-Met;

(ii) Pro-Leu-Pro-Gln-Met-Leu; and

(iii) Thr-Asn-Pro-Asn-Arg-Arg-Asn-Arg-Thr-Pro-Gln-Met-Leu-Lys-Arg;

or a functional variant thereof.

5 28. A peptide according to claim 26 that binds at or near a copper binding site of A β and physically prevents the binding of copper.

29. A peptide according to claim 26 wherein the peptide binds at or near amino acids 5-14 of human A β .

10

30. A peptide according to claim 26 wherein the peptide binds at or near amino acids 8-14 of human A β .

31. A peptide according to 26 wherein the peptide binds at or near amino acid 13 of human A β .

15

32. A peptide according to claim 26 that binds to A β and disrupts the conformation (or 3-D structure) of the copper binding site to reduce or totally remove its ability to bind copper and/or its SOD activity.

20

33. A peptide according to claim 32 that binds and disrupts the conformation of amino acids 5-14 of human A β .

34. A peptide according to claim 32 that binds and disrupts the conformation of amino acids 8-14 of human A β .

25

35. A peptide according to claim 32 that binds and disrupts the conformation of amino acid 13 of human A β .

30 36. A peptide according to claim 26 that binds to A β and reduces or totally removes its SOD activity whilst still allowing the A β to bind copper.

37. A functional variant of the peptides of claim 26 or 27.
38. A non-peptide peptidomimetic of a peptide according to claim 26 or 27.
- 5 39. A polynucleotide encoding a peptide according to claims 26 or 27.
40. The use of a peptide according to claim 26 or 27 for designing a mimetic thereof.
- 10 41. A method for reducing or removing SOD activity or inhibiting the copper binding ability of a causative agent, the method comprising contacting the causative agent with a peptide identified using the screen of the present invention such that the peptide binds to the causative agent in a fashion that at least reduces its SOD and/or copper binding activity.
- 15 42. A method for destabilizing multimeric forms of A β , the method comprising contacting the multimeric A β with a peptide of the present invention such that the peptide binds to the multimeric A β in a fashion that destabilizes the multimeric A β .
- 20 43. A method for limiting or preventing the aggregation of A β , the method comprising contacting the A β with a peptide of the present invention such that the peptide binds to the A β and prevents or limits its aggregation.
- 25 44. A method of treating a disease or disorder selected from the group comprising type II diabetes, AD, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE) comprising the step of administering an effective amount of a peptide identified using
- 30 the screening method of the present invention.

45. A pharmaceutical composition comprising a peptide according to claim 26 or 27 and a pharmaceutically acceptable carrier or diluent.

46. A method for isolating candidate peptides for the treatment of AD, the
5 method comprising the steps of:
- (i) contacting a plurality of candidate peptides with a first agent that is adapted to bind peptides that specifically bind to the zinc binding site of A β and isolating the bound peptides; and
 - (ii) contacting the peptides isolated from step (i) with a second agent that is
10 adapted to bind peptides isolated from step (i) that do not specifically bind to the zinc binding site of A β and isolating the unbound peptides;
- wherein the peptides isolated from step (ii) are candidate peptides for AD treatment.

ABSTRACT

A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of:

5 (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and isolating the bound peptides; and (ii) contacting the peptides isolated from step (i) with a second agent structurally related to the first agent but without SOD activity and isolating the unbound peptides; wherein the peptides isolated from step (ii) are candidate peptides for treatment of the disease. Peptides identified using the screening method may be used to treat AD, type II

10 diabetes, Scrapie and Transmissible Spongiform Encephalopathies such as Creutzfeldt Jacob disease (CJD), variant CJD, Gerstmann Strausler Schinkler syndrome and Bovine Spongiform Encephalopathy (BSE).